ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 8, Issue 1, Pages e000673
Publisher
BMJ
Online
2020-04-22
DOI
10.1136/jitc-2020-000673
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Signaling and Function of Interleukin-2 in T Lymphocytes
- (2018) Sarah H. Ross et al. Annual Review of Immunology
- IL-2/CD25: A Long-Acting Fusion Protein That Promotes Immune Tolerance by Selectively Targeting the IL-2 Receptor on Regulatory T Cells
- (2018) Natasha C. Ward et al. JOURNAL OF IMMUNOLOGY
- NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
- (2016) D. H. Charych et al. CLINICAL CANCER RESEARCH
- Low-Dose IL-2 in the Treatment of Lupus
- (2016) Masayuki Mizui et al. Current Rheumatology Reports
- The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder
- (2016) Alexander S. Baras et al. OncoImmunology
- Immunotherapy of melanoma: Present options and future promises
- (2015) Anand Rotte et al. CANCER AND METASTASIS REVIEWS
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- The IL-2 cytokine family in cancer immunotherapy
- (2014) Geok Choo Sim et al. CYTOKINE & GROWTH FACTOR REVIEWS
- CD27 Defines Phenotypically and Functionally Different Human NK Cell Subsets
- (2014) M. T. M. Vossen et al. JOURNAL OF IMMUNOLOGY
- Regression of Metastatic Clear Cell Kidney Cancer With Interleukin-2 Treatment Following Nivolumab (Anti-PD-1) Treatment
- (2014) Jason Brayer et al. JOURNAL OF IMMUNOTHERAPY
- Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program
- (2014) Roxanne Payne et al. Journal for ImmunoTherapy of Cancer
- IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients
- (2013) Geok Choo Sim et al. JOURNAL OF CLINICAL INVESTIGATION
- Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2
- (2013) Jonathan Sitrin et al. JOURNAL OF EXPERIMENTAL MEDICINE
- IL-2–dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells
- (2013) Georg Gasteiger et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild Type IL-2
- (2013) T. Carmenate et al. JOURNAL OF IMMUNOLOGY
- The Ratios of CD8+ T Cells to CD4+CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer
- (2013) Claudia C. Preston et al. PLoS One
- Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial
- (2013) Agnès Hartemann et al. Lancet Diabetes & Endocrinology
- ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4+T cells by plasmacytoid dendritic cells
- (2013) Julien Faget et al. OncoImmunology
- Fusion protein linkers: Property, design and functionality
- (2012) Xiaoying Chen et al. ADVANCED DRUG DELIVERY REVIEWS
- ICOS-Dependent Homeostasis and Function of Foxp3+ Regulatory T Cells in Islets of Nonobese Diabetic Mice
- (2012) M. Kornete et al. JOURNAL OF IMMUNOLOGY
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
- (2012) Aron M. Levin et al. NATURE
- A Human Disease Model of Drug Toxicity–Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice
- (2012) Dongeun Huh et al. Science Translational Medicine
- CD11b and CD27 reflect distinct population and functional specialization in human natural killer cells
- (2011) Binqing Fu et al. IMMUNOLOGY
- Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases
- (2011) John Puskas et al. IMMUNOLOGY
- IL-2 Induces Conformational Changes in Its Preassembled Receptor Core, Which Then Migrates in Lipid Raft and Binds to the Cytoskeleton Meshwork
- (2010) Anne-Hélène Pillet et al. JOURNAL OF MOLECULAR BIOLOGY
- Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
- (2010) C. Krieg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
- (2010) H.-T. Jin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The High-Dose Aldesleukin (IL-2) “Select” Trial: A Trial Designed to Prospectively Validate Predictive Models of Response to High-Dose IL-2 Treatment in Patients With Metastatic Renal Cell Carcinoma
- (2009) Jessica M. Clement et al. Clinical Genitourinary Cancer
- IL-2– and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets
- (2009) Sven Létourneau et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- CD56brightnatural killer (NK) cells: an important NK cell subset
- (2008) Aurélie Poli et al. IMMUNOLOGY
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
- (2008) Shawn D Blackburn et al. NATURE IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started